Onconetix, Inc. (NASDAQ:ONCO – Free Report) shares are set to reverse split on Friday, November 6th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 5th.
Onconetix Trading Up 26.0%
NASDAQ:ONCO opened at $0.60 on Thursday. The firm has a market capitalization of $3.13 million, a price-to-earnings ratio of 0.00 and a beta of 2.61. Onconetix has a 1-year low of $0.34 and a 1-year high of $200.00. The business’s fifty day moving average price is $0.66 and its 200 day moving average price is $15.84.
Onconetix (NASDAQ:ONCO – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4,505.00) by $4,503.72. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.
Analyst Ratings Changes
A number of analysts have recently issued reports on ONCO shares. Weiss Ratings lowered shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, October 13th. Wall Street Zen upgraded shares of Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Onconetix has an average rating of “Sell”.
Check Out Our Latest Report on ONCO
Onconetix Company Profile
Onconetix, Inc is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions.
Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.
Featured Articles
- Five stocks we like better than Onconetix
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
